Onconetix
NASDAQ: ONCOCincinnati, US · Founded 2018 · Delaware corporation
Onconetix is a commercial-stage biotechnology company that researches, develops, and commercializes proprietary therapeutics, diagnostics, and services in oncology. It serves clinicians and patients, with a product line that includes the Proclarix diagnostic.
Founders & leadership
KF
Karina FedaszExecutive
RS
Ralph SchiessExecutive
JH
Joseph HernandezNamed on SEC filing
Board
TR
Timothy RamdeenBoard director
AS
Ajit SinghBoard director
ST
Simon TarshBoard director
TM
Thomas MeierBoard director
JS
James SapirsteinBoard director
Reported raises · per SEC filings
Form D private placements$22M disclosed across 3 rounds · 2019–2025
▶$13MraisedOct 2025 · 11 investors · BiotechnologyRule 506(b)
▶$13MraisedOct 2025 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Simon TarshDirector
- Karina FedaszExecutive Officer
- Andrew OakleyDirector
- Timothy RamdeenDirector
- Thomas MeierDirector
- Offering amount
- $13M
- Amount sold
- $13M
- Minimum investment
- $208.8K
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedOct 2024 · 5 investors · BiotechnologyRule 506(b)
▶$2MraisedOct 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Simon TarshDirector
- Karina FedaszExecutive Officer
- Thomas MeierDirector
- Timothy RamdeenDirector
- James SapirsteinDirector
- Ajit SinghDirector
- Ralph SchiessExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- Sales commissions
- $160K
- Placement agents
- Finalis Securities, LLC
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedJul 2019 · 5 investors · BiotechnologyRule 506(b)
▶$7MraisedJul 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph HernandezExecutive Officer
- Offering amount
- $7M
- Amount sold
- $7M
- Proceeds to insiders
- $300K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapSimply Wall St13 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Perplexity13 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies competing with Onconetix for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Onconetix do?
- Onconetix is a commercial-stage biotechnology company that researches, develops, and commercializes proprietary therapeutics, diagnostics, and services in oncology. It serves clinicians and patients, with a product line that includes the Proclarix diagnostic.
- How much funding has Onconetix raised?
- Onconetix has disclosed $22M raised across 3 rounds.
- Where is Onconetix headquartered?
- Onconetix is headquartered in Cincinnati, US.